why choose us

First received: October 20, 2023

Clinical Trial: Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) in Prevention of HIV in Cisgender Women in the United States (HPTN-102)

Study Status: Completed

Recruit Status: RECRUITING

Condition: Pre-Exposure Prophylaxis of HIV Infection

Study Type: INTERVENTIONAL


Official Title: A Phase 2, Open-label, Multicenter, Randomized Study to Evaluate the Pharmacokinetics, Safety, and Acceptability of Twice Yearly Long-acting Subcutaneous Lenacapavir for Pre-Exposure Prophylaxis in Ci

Brief Summary: The goal of this clinical study is to look at how lenacapavir (LEN) passes through the body and to assess the safety of LEN and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) for prevention of HIV in the Cisgender women in the US.The primary objectives of this study are:To characterize the pharmacokinetics (PK) of LEN in United States (US) cisgender women.To evaluate the safety of LEN and F/TDF for pre-exposure prophylaxis (PrEP) in US cisgender women.To evaluate the general acceptability of…

Read more